NEXT-GEN CELL THERAPIES

Ready-to-graft microtissue formats

To unleash the therapeutic potential of stem cell-derived cell therapies

AN OPEN INNOVATION PIPELINE

Our goal is to bring the benefits of C-Stem™ as fast as possible to patients. To do so, we advance proprietary cell therapy programs and partner with leading initiatives from the industry and the academia.

pipeline-iPS-based-cell-therapies-TreeFrog-Therapeutics
Lead programme

Neural microtissues to cure Parkinson's disease

In contrast with cell therapy approaches based on the transplantation of single cells, the C-Stem™ technology generates 3D neural microtissues containing mature dopaminergic neurons. 

Since 2018, preclinical studies demonstrated robust in vivo effects and safety profile, with fast and complete motor function recovery. 

Aiming at a first-in-human trial in 2025, TreeFrog is now moving forward with regulatory toxicology studies and is transferring the GMP C-Stem™ platform to a CDMO to manufactur clinical-grade batches.

Neural microtissue containing mature dopaminerguic neurons differentiated
from human induced pluripotent stem cells cultured in 3D using C-Stem™ technology

Co-development & Licensing opportunities

Contact our team


    Cell Therapy Pipeline I iPS-derived cell therapies I Allogeneic Stem Cell Therapies

    TreeFrog Therapeutics is advancing a pipeline of hiPSC-derived cell therapies based on the C-Stem technology. Our lead programme is an iPS-based cell therapy for Parkinson’s disease, which will reach IND and Phase I in 2025. We are also developing allogeneic therapies for heart failure with hiPSC-derived cardiac cells, iPS-derived HSC transplants with the EFS, iPS-derived CAR & NK cell therapies for oncology, iPS-derived cell therapies for AMD, as well as exploratory cell therapies for hepatic and pancreatic diseases (acute liver failure and Diabetes Type I)